Adrian N. Hobden
United States of America
Adrian Hobden has had a long and distinguished career in the global pharmaceutical industry. He earned his Bachelors and Masters degrees in Biochemistry from Cambridge University and a PhD in Molecular Biology from Leicester University, both in the United Kingdom (UK). After a postdoctoral fellowship with the Medical Research Council in the UK, he joined Glaxo as a research scientist. He was their first molecular biologist recruit worldwide and went on to run their Genetics Department and several other departments, including CNS Pharmacology. Hobden moved to the United States in 1996 and was responsible for Glaxo’s collaborations with biotechnology companies. In 1998, he joined Myriad Genetics in Salt Lake City as president of Myriad Pharmaceuticals. Myriad was later spun out as a public company called Myrexis with Hobden as CEO. Hobden, who retired in 2011, serves on the Board of Directors of Zocere and The Hope Fund for Cancer Research. He also is assisting a startup biotechnology company in New York studying cancer stem cells. Hobden has been involved in development of a number of pharmaceuticals in a range of disease areas, including cancer, Alzheimer’s disease, cardiovascular, respiratory, HIV, and anti-fungals.
Pharmacology Molecular Biology Biotechnology